Drug Information

Drug (ID: DG01696) and It's Reported Resistant Information

Name	Gemcitabine/LY2780301
Synonyms	Gemcitabine/LY2780301 Click to Show/Hide
Target	.	NOUNIPROTAC	[1]

Type(s) of Resistant Mechanism of This Drug

UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Cervical cancer [ICD-11: 2C77]

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Unusual Activation of Pro-survival Pathway (UAPP)		Click to Show/Hide
Key Molecule: PI3-kinase alpha (PIK3CA)			[1]
Molecule Alteration	Missense mutation	p.E542K (c.1624G>A)	Molecule Info
Sensitive Disease	Cervical cancer [ICD-11: 2C77.0]		Disease Info
Experimental Note	Identified from the Human Clinical Data
Cell Pathway Regulation	PI3K signaling pathway	Inhibition	hsa04151

References

Ref 1	Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation studyEur J Cancer. 2017 Sep;83:194-202. doi: 10.1016/j.ejca.2017.06.036. Epub 2017 Jul 24.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.